Porto Alegre, RIO%20GRANDE%20DO%20SUL1 Active Studies

Gaucher Disease Clinical Trials in Porto Alegre, RIO%20GRANDE%20DO%20SUL

Find 1 actively recruiting gaucher disease clinical trials in Porto Alegre, RIO%20GRANDE%20DO%20SUL. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
15
Enrolling

Recruiting Gaucher Disease Studies in Porto Alegre

About Gaucher Disease Clinical Trials in Porto Alegre

Gaucher disease is an inherited metabolic disorder caused by deficiency of the enzyme glucocerebrosidase, leading to accumulation of fatty substances in organs. It is the most common lysosomal storage disorder. Treatment includes enzyme replacement therapy and substrate reduction therapy.

There are currently 1 gaucher disease clinical trials recruiting participants in Porto Alegre, RIO%20GRANDE%20DO%20SUL. These studies are seeking a combined 15 participants. Research is being sponsored by Prevail Therapeutics. Clinical trial participation is free and participants receive study-related medical care at no cost.

Gaucher Disease Clinical Trials in Porto Alegre — FAQ

Are there gaucher disease clinical trials in Porto Alegre?

Yes, there are 1 gaucher disease clinical trials currently recruiting in Porto Alegre, RIO%20GRANDE%20DO%20SUL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Porto Alegre?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Porto Alegre research site will contact you about next steps.

Are clinical trials in Porto Alegre free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Porto Alegre studies also compensate for your time and travel.

What gaucher disease treatments are being tested?

The 1 active trials in Porto Alegre are testing new therapies including novel drugs, biologics, and treatment approaches for gaucher disease.

Data updated March 2, 2026 from ClinicalTrials.gov